欧洲多中心研究:妊娠相关黑色素瘤的流行病学特征
该欧洲多中心回顾性研究纳入2012至2022年5国6中心1270例15-49岁女性黑色素瘤患者,其中70例(5.5%)为妊娠相关黑色素瘤(PAM)。PAM患者更年轻且痣计数更多,57.1%发生于原有痣,但两组无复发生存无显著差异,5年无复发生存率约95%。
要点
- PAM占育龄女性黑色素瘤的5.5%,各中心范围1.2%-14.3%。
- PAM患者更年轻(平均35.7岁)且更常见高痣计数。
- 57.1%的PAM发生于原有痣,提示孕期需皮肤科评估可疑皮损。
核心结论
- 妊娠似乎不 adverse 影响黑色素瘤预后,但PAM具有一些独特的临床特征。
研究设计与样本
- 欧洲5国6个黑色素瘤中心的回顾性多中心研究,纳入2012至2022年诊断的1270例15-49岁女性黑色素瘤患者。
主要发现
- 70例(5.5%)归类为PAM,各中心范围为1.2%-14.3%。
- PAM患者较非PAM更年轻(平均年龄35.7岁,p < 0.001)且更可能具有高痣计数(p = 0.031)。
- 80.0%的PAM为浅表扩散型,平均Breslow厚度1.16 mm,12.9%伴溃疡。
- 57.1%的PAM发生于原有痣。
- 非PAM肿瘤的肿瘤浸润淋巴细胞(TILs)显著更密集(p = 0.012);中位随访5.5年,两组无复发生存无显著差异,5年无复发生存率为95%。
临床怎么用
- 孕期发现可疑色素性皮损应积极进行皮肤科评估,尤其关注原有痣的变化。
- 妊娠本身不应被视为黑色素瘤预后不良的因素。
局限性
- 回顾性设计,PAM各中心比例差异较大(1.2%-14.3%)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Melanoma is the most common malignancy during pregnancy, with incidence rates rising globally. While most studies focus on prognosis, limited data exist on melanoma in the early post-partum period. OBJECTIVES: This multicentre European study aimed to characterize the epidemiologic and clinicopathologic features of pregnancy-associated melanoma (PAM) and assess whether these tumours differ from melanomas not associated with pregnancy. METHODS: We identified 1,270 women of reproductive age (15-49 years) diagnosed with melanoma between 2012 and 2022 across six melanoma centres in five European countries. RESULTS: Among them, 70 cases (5.5%) were classified as PAM (range: 1.2%-14.3%). Compared to non-PAM patients, women with PAM were younger (mean age 35.7 years; p < 0.001) and more likely to have a high nevus count (p = 0.031). The majority of PAMs (80.0%) were superficial spreading, and mean Breslow thickness was 1.16 mm; 12.9% were ulcerated. Notably, 57.1% developed on a pre-existing nevus. Histopathologic features were similar between groups, except for tumour-infiltrating lymphocytes (TILs): non-PAM tumours exhibited significantly more dense TILs (p = 0.012), possibly indicating a stronger immune response. Median follow-up was 5.5 years. Recurrence-free survival did not significantly differ between groups; the 5-year recurrence-free survival rate was 95%. CONCLUSIONS: Although pregnancy does not appear to adversely impact melanoma prognosis, PAM demonstrates some distinct clinical features that warrant further investigation given the fact that it affects a substantial proportion of women of reproductive age diagnosed with melanoma. The frequent occurrence of PAM on pre-existing nevi highlights the importance of raising public awareness and promoting dermatologic evaluation of suspicious lesions during pregnancy. Melanoma is the most common cancer during pregnancy. Pregnancy‐associated melanoma (PAM) is the melanoma that is diagnosed during pregnancy or up to one year post‐partum. This multicentre European study aimed to assess whether these tumours differ from melanomas that are not associated with pregnancy (non‐PAM). We retrospectively identified 1270 women of reproductive age (15–49 years) who were diagnosed with melanoma between 2012 and 2022. Among them, 70 women (around 1 out of 20) had PAM. Compared to non‐PAM patients, women with PAM were younger and more likely to have a large number of moles. The majority of PAM developed on a pre‐existing nevus. The features of melanoma were mostly similar among pregnant and non‐pregnant women, although pregnant women might have a less favourable immune response. Pregnancy did not worsen outcomes. About 95% of women in both groups remained disease‐free 5 years after diagnosis. These findings suggest that while pregnancy does not worsen melanoma outcomes, melanoma during pregnancy has some unique characteristics. Because of the frequent occurrence of PAM on pre‐existing nevi, it is important for pregnant women to check their skin regularly and seek dermatological evaluation in case of suspicious lesions.
引用
- Kostaki M, Plaka M, Chardalia V, et al. Pregnancy-associated melanoma epidemiology: A multicentre European study. J Eur Acad Dermatol Venereol. 2025. PMID: 41133989. doi:10.1111/jdv.70134
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。